Literature DB >> 19101649

PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.

Mallika Ghosh1, Youxi Ai, Kirsi Narko, Zhenglong Wang, Jeffrey M Peters, Timothy Hla.   

Abstract

Cyclooxygenase-2 (COX-2), overexpressed in inflammatory conditions and cancer, regulates angiogenesis and tumorigenesis via the production of biologically active prostanoids. Previously, we showed that COX-2 over-expression in the mammary gland of transgenic mice induces an angiogenic switch and transforms the mammary epithelium into invasive mammary carcinoma. Since COX-2-derived prostanoids can activate the nuclear receptor PPARdelta, we crossed Ppardelta(-/-) mice with COX-2 transgenic mice in the FVB/N background. PPARdelta was expressed constitutively in the mammary gland of virgin, pregnant and lactating mice. Mammary hyperplasia and tumorigenesis in the COX-2 transgenic mice was markedly reduced in the Ppardelta(-/-) mice compared to their wild type counterparts. Analysis of the mammary tissues indicated that immunoreactive Ki-67, cyclin D1 and phosphorylated histone 3 (Phospho H3) were reduced in Ppardelta(-/-) mice, suggesting that PPARdelta activation regulates cell proliferation in the mammary gland. We postulate that activation of the nuclear receptor PPARdelta by COX-2-derived prostanoids may be involved in the proliferation of mammary epithelial cells and therefore contribute to mammary cancer development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101649      PMCID: PMC2662999          DOI: 10.1016/j.prostaglandins.2008.11.004

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  31 in total

1.  Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps.

Authors:  Masahiro Sonoshita; Kazuaki Takaku; Masanobu Oshima; Ken-ichi Sugihara; Makoto M Taketo
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.

Authors:  C H Liu; S H Chang; K Narko; O C Trifan; M T Wu; E Smith; C Haudenschild; T F Lane; T Hla
Journal:  J Biol Chem       Date:  2001-03-07       Impact factor: 5.157

3.  Cyclooxygenase-2 promotes prostate cancer progression.

Authors:  Hiroshi Fujita; Kiyoshi Koshida; Evan T Keller; Yoshitake Takahashi; Tanihiro Yoshimito; Mikio Namiki; Atsushi Mizokami
Journal:  Prostate       Date:  2002-11-01       Impact factor: 4.104

4.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

Review 5.  COX-2 inhibitors. A new class of antiangiogenic agents.

Authors:  J L Masferrer; A Koki; K Seibert
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

6.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.

Authors:  R A Gupta; J Tan; W F Krause; M W Geraci; T M Willson; S K Dey; R N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

7.  Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta).

Authors:  J M Peters; S S Lee; W Li; J M Ward; O Gavrilova; C Everett; M L Reitman; L D Hudson; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

8.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

Authors:  Ari Ristimäki; Anna Sivula; Johan Lundin; Mikael Lundin; Tiina Salminen; Caj Haglund; Heikki Joensuu; Jorma Isola
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

9.  Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.

Authors:  Sung-Hee Chang; Catherine H Liu; Rebecca Conway; David K Han; Kasem Nithipatikom; Ovidiu C Trifan; Timothy F Lane; Timothy Hla
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

Review 10.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

View more
  17 in total

1.  Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation.

Authors:  Hongyan Yuan; Geeta Upadhyay; Yuzhi Yin; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-28

Review 2.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity.

Authors:  Pei-Li Yao; Jose L Morales; Bokai Zhu; Boo-Hyon Kang; Frank J Gonzalez; Jeffrey M Peters
Journal:  Mol Cancer Ther       Date:  2014-01-24       Impact factor: 6.261

4.  PPARδ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation.

Authors:  Hongyan Yuan; Jin Lu; Junfeng Xiao; Geeta Upadhyay; Rachel Umans; Bhaskar Kallakury; Yuhzi Yin; Michael E Fant; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2013-06-27       Impact factor: 12.701

5.  Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line.

Authors:  Jennifer E Foreman; Arun K Sharma; Shantu Amin; Frank J Gonzalez; Jeffrey M Peters
Journal:  Cancer Lett       Date:  2009-08-05       Impact factor: 9.756

6.  PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis.

Authors:  Claire B Pollock; Yuzhi Yin; Hongyan Yuan; Xiao Zeng; Sruthi King; Xin Li; Levy Kopelovich; Chris Albanese; Robert I Glazer
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

7.  Induction of metastatic gastric cancer by peroxisome proliferator-activated receptorδ activation.

Authors:  Claire B Pollock; Olga Rodriguez; Philip L Martin; Chris Albanese; Xin Li; Levy Kopelovich; Robert I Glazer
Journal:  PPAR Res       Date:  2010-12-27       Impact factor: 4.964

8.  PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.

Authors:  Joseph Vamecq; Jean-Marie Colet; Jean Jacques Vanden Eynde; Gilbert Briand; Nicole Porchet; Stéphane Rocchi
Journal:  PPAR Res       Date:  2012-05-08       Impact factor: 4.964

9.  Artesunate attenuates proliferation of epithelial cells by downregulating the NF-κB and AKT signaling pathways in benign mammary gland hyperplasia rats.

Authors:  Wei Li; Lina Zhao; Yiliang Li; Zhen Zhai
Journal:  Ann Transl Med       Date:  2021-05

10.  Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.

Authors:  Keehoon Jung; Takahiro Heishi; Joao Incio; Yuhui Huang; Elizabeth Y Beech; Matthias Pinter; William W Ho; Kosuke Kawaguchi; Nuh N Rahbari; Euiheon Chung; Jun Ki Kim; Jeffrey W Clark; Christopher G Willett; Seok Hyun Yun; Andrew D Luster; Timothy P Padera; Rakesh K Jain; Dai Fukumura
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.